Melanoma Archives

In Depth 16 Aug 2023

Can a vaccine be the solution to the surge in melanoma cases caused by the climate crisis?

Melanoma is the most serious type of skin cancer, and is primarily caused by too much exposure to ultraviolet (UV) light – in the U.K., around 85% of melanomas are thought to be caused by too much ultraviolet radiation. And, unfortunately, because of this, the surge in global temperatures caused by the climate crisis is […]

August 16, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 16 Feb 2023

Cytovation melanoma study under way

Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […]

February 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Proscia presents results on AI melanoma diagnostic predictions

Proscia has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer. The findings, presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance. Conducted at […]

November 1, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

OncoSec slashing staff numbers to prioritize pipeline

OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

Using the power of proteomics to predict immunotherapy responses in melanoma and beyond

Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care. The recent success of immunotherapies that manipulate the patient’s immune system to recognize […]

September 27, 2022 - 6 minutesmins - By External Contributor

News and Trends 22 Sep 2022

Swiss scientists reduce resistance of dormant melanoma cells

Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

cancer vaccine virus ervaxx cell therapy

News and Trends 6 Nov 2019

UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines

The London-based startup Ervaxx has launched with a €15.8M Series A round to develop cancer vaccines and cell therapies that target ‘dark antigens’ — normally silent genes in the genome that are expressed in cancer cells. Ervaxx’s Series A round was funded by the transatlantic venture capital firm SV Health Investors, as well as an […]

November 6, 2019 - 2 minutesmins - By Jonathan Smith

cancer cell therapy immunotherapy achilles therapeutics

News and Trends 3 Sep 2019

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […]

September 3, 2019 - 2 minutesmins - By Jonathan Smith

melanoma yukin therapeutics antibody cancer nice

Startup Scout 5 Jul 2019

This Biotech Helps the Immune System to Infiltrate and Destroy Tumors

The Nice-based biotech company Yukin Therapeutics is developing drugs that can work together with checkpoint inhibitors to help the immune system smash tumors such as melanoma. Mission: To develop a drug that can change the tumor microenvironment to allow the immune system to infiltrate and destroy the tumor more effectively. This could give a big […]

July 5, 2019 - 3 minutesmins - By Jonathan Smith

Interview 24 Jul 2018

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”

Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […]

July 24, 2018 - 6 minutesmins - By Editorial Team

News and Trends 12 Dec 2017

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […]

December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Nov 2017

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […]

November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us